NKTR-255 is an experimental PEG-conjugated IL-15R agonist aimed at increasing the intrinsic anticancer capacity of the immune system by promoting the survival and expansion of tumor-killing NK cells as well as memory CD8+ T lymphocytes (85, 86). The gene discussed is CD8A; the disease is neoplasm.